TScan Therapeutics Cuts 75% of Workforce to Focus on Solid Tumor Programs
TScan Therapeutics has announced that it will be reducing its workforce by 75% after pausing further development in its hematological and autoimmune programs. The company's CEO, Gavin MacBeath, Ph.D., stated that this decision is aimed at maximizing value for both patients and shareholders with the reorganized company.
The company had previously announced a collaboration with Amgen worth $500 million, but the deal was abandoned last month. TScan had told Fierce that its pipeline strategy remained unchanged, while Amgen cited a strategic review of their portfolio as the reason for ending the partnership.
TScan is now prioritizing its preclinical solid tumor programs, which target abnormally expressed proteins in cancer using an in vivo-engineered TCR-T cell therapy. The company believes this approach will address manufacturing and cost issues associated with autologous TCRs.